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Abstract
Background: Radiation therapy is an important cancer treatment modality in both adjuvant and definitive setting,
however, the use of radiation therapy for elective treatment of regional lymph nodes is controversial for pancreatic
cancer. No consensus on proper selection and delineation of subclinical lymph nodal areas in adjuvant or definitive
radiation therapy has been suggested either conclusively or proposed for further investigation. This analysis aims to
study the pattern of lymph node metastasis through a pooled analysis of published results after radical tumor and
lymph nodal resection with histological study in pancreatic cancer.
Methods: Literature search using electronic databases including MEDLINE, EMBASE, and CANCERLIT from January
1970 to June 2009 was performed, supplemented by review of references. Eighteen original researches and a total
of 5954 pancreatic cancer patients underwent radical surgical resection were included in this analysis. The
probability of metastasis in regional lymph nodal stations (using Japan Pancreas Society [JPS] Classification) was
calculated and analyzed based on the location and other characteristics of the primary disease.
Results: Commonly involved nodal regions in patients with pancreatic head tumor include lymph nodes around
the common hepatic artery (Group 8, 9.79%), posterior pancreaticoduodenal lymph nodes (Group 13, 32.31%),
lymph nodes around the superior mesenteric artery (Group 14, 15.85%), paraaortic lymph nodes (Group 16,
10.92%), and anterior pancreaticoduodenal lymph nodes (Group 17, 19.78%); The probability of metastasis in other
lymph nodal regions were <9%.
Commonly involved nodal regions in patients with pancreatic body/tail tumor include lymph nodes around the
common hepatic artery (Group 8, 15.07%), lymph nodes around the celiac trunk (Group 9, 9.59%), lymph nodes
along the splenic artery (Group 11, 35.62%), lymph nodes around the superior mesenteric artery (Group 14, 9.59%),
paraaortic lymph nodes (Group 16, 16.44%), and inferior body lymph nodes (Group 18, 24.66%). The probability of
metastasis in other lymph nodal regions were <9%.
Conclusions: Pancreatic cancer has a high propensity of regional lymphatic metastases; however, clear patterns
including the site and probability of metastasis can be identified and used as a guide of treatment in patients
with resectable pancreatic cancer. Further clinical investigation is needed to study the efficacy of elective
treatment to CTV defined based on these patterns using high-dose conformal or intensity-modulated radiation
therapy.
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Pancreatic cancer is a highly malignant neoplasm of GI
system, and radical surgery is its only curative treatment
option [1]. Unfortunately, the probability of locoregional
recurrence approaches 80% after complete resection,
and long-term survival is less than 25% even for patients
treated for early stage disease [2-4]. Adjuvant treatment
is an integral part of definitive treatment of resectable
pancreatic carcinoma; however, the optimal therapeutic
modalities in adjuvant setting remain a focus of debate.
Radiation therapy is commonly used in adjuvant treat-
ment for pancreatic cancer after radical surgery in the
United States. The effect of radiation with concurrent
5-FU based chemotherapy has been suggested in a num-
ber of randomized clinical trials [5-7]. In addition, con-
current chemoradiation therapy has been the mainstay
treatment for nonmetastatic and inoperable pancreatic
cancer [8,9].
Radiation fields utilized in these trials encompassed
not only subclinical nodal regions but also adjacent nor-
mal tissues. Despite such generous coverage, however,
locoregional control remains a major mode of recur-
rence. The underlying reason for such suboptimal out-
come is probably due to, at least in part, insufficient
radiation dose (i.e., 45-50 Gy in conventional fractiona-
tion) to the surgical bed and draining lymph node
regions limited by the organs at risk (OARs) adjacent to
t h ep a n c r e a sa n dl y m p hn o d a lr e g i o n ss u c ha sl i v e r ,
small intestine, stomach, spinal cord, and kidneys.
The prevailing utilization of intensity-modulated radia-
tion therapy (IMRT) in cancer treatment including
upper GI malignancies enabled dose differentiation
between target volumes and adjacent normal tissues and
organs thereby improved therapeutic ratio. Results from
recently published dosimetry studies have suggested the
advantage of IMRT in the treatment of tumors of upper
abdomen including pancreatic, gastric, and billiary can-
cers as compared to 3-dimentional conformal radiation
therapy (3D-CRT) [10-13]. Proper defining of high-risk
regions especially the lymph nodal regions (i.e., CTV-N)
forms an imperative basis for dose escalation using
IMRT. However, selection and delineation of nodal
regions in both adjuvant IMRT after pancreaticoduode-
nectomy and in definitive setting have never been
addressed.
The aim of this analysis is to address the selection of
high-risk subclinical lymph nodal regions in conformal
radiation therapy for resectable pancreatic cancer, by
reviewing and summarizing the probability of lymph
node metastases in resectable pancreatic cancer patients
treated with radical surgery with lymph node dissection
and pathological investigation of the resected regional
nodes.
Methods
An exhaustive search and review of original articles ana-
lyzing lymph nodal positivity rate of pancreatic cancer
was performed by searching MEDLINE, EMBASE, and
CANCERLIT from January 1970 to June 2009. The
search strategy used the following key words in various
combinations: “pancreatic cancer”, “pancreatic carci-
noma”, “lymph node”,a n d“surgery”. Based on the titles
of the articles, studies not describing the pattern of
lymph nodal metastasis were excluded, and the entire
article of those retained and published in English were
read and screened. Studies were eligible if lymph node
positivity rates in pancreatic cancer were reported. We
also supplemented correlative articles by reading the
references of reviews.
All lymph nodes were classified according to the Gen-
eral Rules for Cancer of the Pancreas published by the
Japan Pancreas Society (JPS) (Figure 1) [14]. Articles in
which dissected lymph nodes could not be classified
according to the rule of JPS were excluded. There was
no restriction criterion on the number of patients
enrolled in the study.
The rate of disease involvement of all lymph nodal
regions (according to JPS Classification) was the primary
outcome. Relationship between lymph nodal metastasis
and tumor characteristics (T classification, lymphatic
vessel invasion, tumor location, tumor size and tumor
differentiation) was also evaluated.
The accuracy of data from individual publication
including the conversion to JPS lymph node classifica-
tion was examined by two participants of this analysis.
Pooled analyses of the rates of metastasis to lymph
nodal regions were calculated and reported. Statistical
correlation between metastasis to lymph node areas and
tumor characteristics was performed using Fisher’s exact
test.
Results
Characteristics of Included Studies
The initial search resulted in 392 citations. The title and
abstract of each retrieved publication were reviewed to
confirm that the article reported on the incidence of
lymph nodal positivity in patients with pancreatic can-
cer. In the event that this approach was not informative,
the full article was retrieved and reviewed in detail. This
process resulted in excluding 373 studies and 19 studies
were selected. Of these 19 studies, one study [15] was
further excluded from this analysis because we could
not classify the lymph nodes of this study according to
the rule of JPS (Figure 2).
In 18 eligible studies [1,16-32], 12 (66.7%) studies
described lymph nodal metastatic rates of pancreatic
head cancer; cancer of body/tail of pancreas in only 2
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Page 2 of 13(11.1%) studies and general pancreatic cancer (including
all locations of pancreas) in 4 (22.2%) studies (Table 1).
In analyzing the metastatic pattern of lymph nodes, we
divided the data of one study about general pancreatic
cancer (Study No.3) [17] into two parts (the data about
pancreatic head cancer and those about pancreatic
body/tail cancer), then integrated these two parts into
the statistical analysis of pancreatic head and body/tail
cancer respectively.
The 18 studies, which met the inclusion criteria,
reported on 5954 pancreatic cancer patients who had
undergone radical lymph nodes dissections (Table 1). 17
studies were prospective, and the remaining one was a
statistic summary of 20 years’ registry results on JPS
website [1]. The median number of pancreatic cancer
patients enrolled per study was 49.5 (range 8-4913
patients). In studies that provided baseline demographic
information on pancreatic cancer patients, 414 were
men and 242 were women [16-23]. The mean age was
reported in 5 studies and ranged between 61 years and
74.8 years [17,23-25,28], and the reported median age
ranged from 59 years to 65 years in 3 studies [16,18,29].
Twelve of 18 (66.7%) studies commented on the histo-
pathologic examination of lymph nodes, which consisted
of routine hematoxylin and eosin staining, with
additional sections evaluated by elastica van Gieson
staining in 4 (33.3%) studies [17,25,26,32] and by elastic-
Masson staining in 1 (8.3%) study [24]. Furthermore, 16
of 18 (88.9%) studies described the histopathologic type
of pancreatic cancer. Of these, almost all enrolled
patients’ histopathologic types were ductal adenocarci-
nomas except for two patients. One patient’s histopatho-
logical type was undifferentiated carcinoma and another
was adenosquamous carcinoma.
Regional lymph node metastasis pattern based on
different locations of tumors
The probability of metastasis in regional lymph nodal
stations was calculated and analyzed by Japan Pancreas
Society (JPS) Classification [14]. For all 5954 patients
with pancreatic cancer (including head and body/tail of
pancreas), commonly involved regional lymph nodal sta-
tions were lymph nodes around the common hepatic
artery (Group8, 9.84%), posterior pancreaticoduodenal
lymph nodes (Group13, 32.1%), lymph nodes around the
superior mesenteric artery (Group14, 15.76%), paraaortic
lymph nodes (Group16, 11.04%), anterior pancreatico-
duodenal lymph nodes (Group17, 19.65%). Nodal sites
with a frequency of metastasis <5% included right car-
dial lymph nodes (Group1, 0.39%), left cardial lymph
Figure 1 JPS Classification of the regional lymph nodes of the pancreas. (Adapted from Nagakawa T, Kobayashi H, Ueno K, Ohta T,
Kayahara M, Mori K, Nakano T, Takeda T, Konishi I, Miyazaki I: The pattern of lymph node involvement in carcinoma of the head of the pancreas.
A histologic study of the surgical findings in patients undergoing extensive nodal dissections. Int J Pancreatol. 1993,13:15-22 [19]. Used with
permission from Springer Science+Business.) Insert: Subdivision of Group 14: (AMS) superior mesenteric artery; (AJ) jejunal artery; (APDI) inferior
pancreaticoduodenal artery; (ACM) medial colic artery; For other abbreviations of the nodal groups refer to Table 2.
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Table 1 Classification of regional lymph nodes of the pancreas
No. of Study Studies Year Location of Tumors No. of Patients LN Positivity
1 Brunner TB [16] 1978-1997 Head 178 NA
2 Matsuno S [1] 1981-2002 Head 4913 NA
3 Kayahara M [17] 1974-1996 General* 99 78%
4 Sierzega M [18] 1980-2002 Head 96 66.70%
5
# Nagakawa T [19] 1973-1989 Head 42 78.60%
6 Nagakawa T [20] 1973-1989 Head 42 78.60%
7 Capussotti L [21] 1988-1998 Head 100 59%
8 Cubilla AL [22] 1974-1976 General* 22 86.40%
9 Nakao A [23] 1981-1995 Body/tail 30 46.70%
10 Nagai H [24] 1980-1983 General* 8 75%
11 Kayahara M [25] 1980-1994 Body/tail 20 80%
12 Kayahara M [26] N/A Head 44 70.50%
13 Yoshida T [27] 1995-1999 Head 34 NA
14 Sakai M [28] 1981-2002 Head 178 66%
15 Gerdes B [29] 1995-2002 Head 50 64%
16 Ishikawa O [30] 1981-1994 Head 81 73%
17 Kayahara M [31] 1973-1991 Head 49 76%
18 Kocher HM [32] N/A General* 10 80%
#The patients of Study No.5 are same as those of Study No.6.
N/A = not applicable; *“General” indicates the location of tumor in that study include either head or body/tail.
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Page 4 of 13nodes (Group2, 0.28%), lymph nodes along the lesser
curvature of the stomach (Group3, 1.2%), lymph nodes
along the greater curvature of the stomach (Group4,
1.37%), suprapyloric lymph nodes (Group5, 1.68%),
lymph nodes around the left gastric artery (Group7,
1.73%), lymph nodes around the celiac trunk (Group9,
3.75%), lymph nodes at the hilus of the spleen
(Group10, 0.84%), lymph nodes along the splenic artery
(Group11, 1.93%), lymph nodes along the middle colic
artery (Group15, 2.7%), inferior body lymph nodes
(Group18, 3.04%) (Table 2, Figure 3).
In 13 studies on pancreatic head cancer (including a
part of data in Study No.3), metastatic rates of regional
lymph nodes of 5838 patients were analyzed. Commonly
involved nodal regions in patients with pancreatic head
tumor included the posterior pancreaticoduodenal
lymph nodes (Group 13, 32.31%), anterior pancreatico-
duodenal lymph nodes (Group 17, 19.78%), lymph
nodes around the superior mesenteric artery (Group 14,
15.85%), paraaortic lymph nodes (Group 16, 10.92%)
and lymph nodes around the common hepatic artery
(Group 8, 9.79%). The probability of lymph nodal
metastasis <5% included right cardial lymph nodes
(Group 1, 0.39%), left cardial lymph nodes (Group 2,
0.28%), lymph nodes along the lesser curvature of the
stomach (Group 3, 1.2%), lymph nodes along the greater
curvature of the stomach (Group 4, 1.38%), suprapyloric
lymph nodes (Group 5, 1.69%), lymph nodes around the
left gastric artery (Group 7, 1.74%), lymph nodes around
the celiac trunk (Group 9, 3.66%), lymph nodes at the
hilus of the spleen (Group 10, 0.78%), lymph nodes
along the splenic artery (Group 11, 1.64%), lymph nodes
along the middle colic artery (Group 15, 2.69%) and
inferior body lymph nodes (Group 18, 2.61%) (Table 2,
Figure 3).
There were 3 studies including 73 patients with cancer
of body/tail of pancreas which were analyzed (including
a part of data in Study No.3). Commonly involved nodal
regions in patients with pancreatic body/tail tumor
included lymph nodes around the common hepatic
artery (Group 8, 15.07%), lymph nodes around the celiac
trunk (Group 9, 9.59%), lymph nodes along the splenic
artery (Group 11, 35.62%), lymph nodes around the
superior mesenteric artery (Group 14, 9.59%), paraaortic
lymph nodes (Group 16, 16.44%), inferior body lymph
nodes (Group 18, 24.66%). The probability of lymph
nodal metastasis <5% included Groups 1-5 and Group 7
(0%), Group 6(3.33%), Group 10(4.11%), Groups 13,15
(2.74%) and Group 17 (1.37%) (Table 2, Figure 3).
Metastatic rates of subgroups of lymph nodes
We also analyzed the metastatic rates of several sub-
groups of lymph nodes based on tumor locations. The
metastatic rates of subgroups of lymph nodes for
patients with pancreatic head cancer were listed in
Table 3 (not including paraaortic lymph nodes). For
patients with pancreatic head cancer, commonly
involved lymph nodal subgroups were 8a, 12b, 13a, 13b,
14a, 14b, 14d, 17a and 17b. However, tumor rarely
spread to proximal and distal splenic lymph nodes (11p,
11d), lymph nodes around the proper hepatic artery
(12a) which had <5% metastatic rates. The distribution
of lymph nodal subgroups (not including paraaortic
lymph nodes) for patients with pancreatic body/tail
tumor was not described in any study.
In addition, the distribution of paraaortic lymph nodes
based on the locations of tumors was analyzed
[17,20,26]. Similar lymph nodal distributions for disease
from pancreatic head cancer and body/tail cancer were
found. Wherever the primary tumors were situated, the
majority of the positive lymph nodes were located in the
areas between the celiac artery and the inferior mesen-
teric artery (metastatic rate of pancreatic head cancer:
17.3%; metastatic rate of pancreatic body/tail cancer:
17.4%), while other areas including those superior to the
celiac artery or inferior to the inferior mesenteric artery
had <2% in metastatic rates. In the areas between the
celiac artery and the inferior mesenteric artery, the posi-
tive lymph nodes were mainly located anterior to the
abdominal aorta (Area pre-aor) and the area between
t h ea b d o m i n a la o r t aa n dt h ei n f e r i o rv e n ac a v a( A r e a
inter) (metastatic rate of pancreatic head cancer: Area
pre-aor 8.6%, Area inter 11.7%; metastatic rate of pan-
creatic body/tail cancer: Area pre-aor 13%, Area inter
13%), while other areas including those posterior and
lateral to the aorta and the vena cava and those anterior
to the vena cava had <4% in metastatic rates.
Correlation between metastasis to lymph nodes and
tumor characteristics
We analyzed the correlation between the metastatic
rates of all groups of lymph nodes and tumor character-
istics (T stage, tumor differentiation, lymphatic vessel
invasion and tumor size). There were three studies
describing the distribution of lymph nodes based on
tumor characteristics, 2 about pancreatic head cancer
and 1 about pancreatic body/tail tumor. Two studies
about pancreatic head cancer analyzed 6 groups of
lymph nodes (according to JPS Classification), including
lymph nodes around the celiac trunk (group 9), lymph
nodes of the hepatoduodenal ligament (group 12), pos-
terior pancreaticoduodenal lymph nodes (group 13),
lymph nodes around the superior mesenteric artery
(group 14), paraaortic lymph nodes (group 16), anterior
pancreaticoduodenal lymph nodes (group 17). Alto-
gether, there were only a few sites where frequency of
spread was correlated with tumor characteristics, includ-
ing group 12 and group 13 (these two groups correlated
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Page 5 of 13Table 2 Metastatic rates of all groups of lymph nodes (According to JPS Classification)
No. Group
No. Study
1
RC
2
LC
3
LCS
4
GCS
5
SP
6
IP
7
LGA
8
CHA
9
CT
10
HS
11
SA
12
HDL
13
PPD
14
SMA
15
MCA
16
PA
17
APD
18
IB
Pancreatic Head
Cancer
1 8/175 2/175 31/175 65/175 17/175 39/175 41/175
2 12/
2974
8/
2768
48/
3796
57/
3928
72/
3973
298/
4167
70/
3697
728/
7453
130/
3697
23/
2759
121/
8260
921/12400 2588/
8503
1182/
7962
97/3364 501/
5134
1524/
8148
84/3266
3* 5/76 3/76 0/76 1/76 11/76 75/76 26/76 0/76 14/76 35/76 0/76
4 0/96 0/96 0/96 0/96 0/96 0/96 0/96 12/96 6/96 1/96 3/96 14/96 11/96 0/96 10/96 0/96
5(6)# 0/42 0/42 0/42 1/42 0/42 6/42 2/42 0/42 2/42 9/42 29/42 16/42 0/42 7/42 17/42 5/20
7 0/100 12/100 6/100 9/100 3/100 22/100 3/100
12 0/44 1/44 0/44 6/44 2/44 0/44 2/44 6/44 28/44 15/44 0/44 7/44 14/44 4/44
13 9/34
14 21/178 0/178 17/178 2/178 0/178 14/178 33/178 83/178 50/178 2/178 34/178 51/178 3/178
15 0/50 0/50
16 2/81 9/81 2/81 1/81 12/81 40/81 38/81 5/81 15/81 30/81
17 6/49 2/49 6/49 48/49 18/49 9/49 27/49
Total
(head)
12/
3070
8/
2864
48/
3984
57/
4116
72/
4255
333/
4627
72/
4138
795/
8119
166/
4538
27/
3451
143/
8696
1046/
13241
2956/
9148
1395/
8803
107/
3981
645/
5909
1739/
8793
96/3680
1Total rate
(head) %
0.39 0.28 1.2 1.38 1.69 7.2 1.74 9.79 3.66 0.78 1.64 7.9 32.31 15.85 2.69 10.92 19.78 2.61
Pancreatic Body/tail Cancer
3* 5/23 1/23 1/23 11/23 3/23 1/23 1/23 1/23 4/23 0/23 9/23
9 0/30 0/30 1/30 0/30 0/30 1/30 0/30 1/30 4/30 1/30 5/30 0/30 0/30 4/30 0/30 4/30 1/30 2/30
11 5/20 2/20 1/20 10/20 3/20 1/20 2/20 1/20 4/20 0/20 7/20
Total
(body/tail)
0/30 0/30 0/30 0/30 0/30 1/30 0/30 11/73 7/73 3/73 26/73 6/73 2/73 7/73 2/73 12/73 1/73 18/73
1Total rate
(Body/tail)%
0 0 0 0 0 3.33 0 15.07 9.59 4.11 35.62 8.22 2.74 9.59 2.74 16.44 1.37 24.66
General Pancreatic Cancer
8 0/22 0/22 10/22 1/22 1/22 2/22
10 0/8 0/8 4/8 4/8 2/8
18 1/10 1/10 1/10 1/10 6/10
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3Table 2: Metastatic rates of all groups of lymph nodes (According to JPS Classification) (Continued)
Total
(general)
1/10 0/30 1/40 15/40 2/32 1/22 4/8 10/40
1Total rate
(general)%
10 0 2.5 37.5 6.25 4.55 50 25
Total patients
Total 12/
3100
8/
2894
48/
4014
57/
4146
72/
4285
335/
4667
72/
4168
806/
8192
173/
4611
30/
3554
169/
8769
1053/
13354
2973/
9261
1404/
8908
110/
4076
661/
5990
1750/
8906
114/
3753
2Total rate% 0.39 0.28 1.2 1.37 1.68 7.18 1.73 9.84 3.75 0.84 1.93 7.89 32.1 15.76 2.7 11.04 19.65 3.04
Abbreviations:
Group1: right cardial lymph nodes (RC)
Group2: left cardial lymph nodes (LC)
Group3: lymph nodes along the lesser curvature of the stomach (LCS)
Group4: lymph nodes along the greater curvature of the stomach (GCS)
Group5: suprapyloric lymph nodes (SP)
Group6: infrapyloric lymph nodes (IP)
Group7: lymph nodes around the left gastric artery (LGA)
Group8: lymph nodes around the common hepatic artery (CHA)
Group9: lymph nodes around the celiac trunk (CT)
Group10: lymph nodes at the hilus of the spleen (HS)
Group11: lymph nodes along the splenic artery (SA)
Group12: lymph nodes of the hepatoduodenal ligament (HDL)
Group13: posterior pancreaticoduodenal lymph nodes (PPD)
Group14: lymph nodes around the superior mesenteric artery (SMA)
Group15: lymph nodes along the middle colic artery (MCA)
Group16: paraaortic lymph nodes (PA)
Group17: anterior pancreaticoduodenal lymph nodes (APD)
Group18: inferior body lymph nodes (IB)
1Total rate (head or body/tail or general) = (patient number with positive nodes in all studies mentioning such group of lymph node)/(patient number of all studies mentioning
such group of lymph node) (for head or body/tail or general)
2Total rate = (patient number with positive nodes in all studies mentioning such group of lymph node)/(patient number of all studies mentioning such group of lymph node) (for all pancreatic cancers)
*The data of Study No.3 was divided into 2 parts according to the location of the tumor.
#Study No.5 had the same patients with Study No.6.
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3with lymphatic vessel invasion). One study about pan-
creatic body/tail cancer analyzed 8 groups of lymph
nodes, including lymph nodes around the common
hepatic artery (group 8), lymph nodes around the celiac
trunk (group9), lymph nodes along the splenic artery
(group 11), lymph nodes of the hepatoduodenal liga-
ment (group 12), posterior pancreaticoduodenal lymph
nodes (group 13), lymph nodes around the superior
mesenteric artery (group 14), paraaortic lymph nodes
(group 16), inferior body lymph nodes (group 18). Even-
tually, there was no significant correlation between dis-
tribution of lymph nodes and tumor characteristics.
Discussion
Pancreatic cancer is a highly aggressive GI malignancy.
The outcome of patients with pancreatic cancer, even
after complete surgical resection for early stage diseases
is usually dismal, and locoregional recurrence is a major
mode of treatment failure in both resected and unre-
sectable cases. Radiation therapy is a major cancer treat-
ment modality in both adjuvant and definitive settings;
however, its use in pancreatic cancer, either definitively
or adjuvantly, has been a focus of debate [33]. The sub-
optimal outcome after radiation therapy is due to, at
least in part, insufficient dose to both gross and subcli-
nical regions [33,34].
Irradiation to a large abdominal volume using conven-
tional radiation to a high dose usually induces severe
treatment-related side effects and complications. The
advances in radiation therapy technology especially the
u s eo fI M R Th a v em a d ep r e c i s i o nt a r g e t i n gw i t hh i g h
dose radiation therapy possible in the treatment of
upper abdominal disease [11,12,35]. However, optimal
strategy of selection and delineation of the subclinical
regional disease in clinical target volume (CTV) in the
treatment of pancreatic cancer has not been addressed.
With more effective chemotherapy for systemic treat-
ment of pancreatic cancer, effective local therapy to
both tumor/surgical bed and the subclinical regional
lymph node regions may become one of the determinis-
tic factors for disease control in the treatment of non-
metastatic pancreatic cancer. As the subclinical involve-
ment of lymph nodes cannot be reliably discovered by
image studies including CT, MRI, and/or PET/CT
[36-38], proper selection and delineation of CTV should
be accounted for the major challenge for radiation
oncologists in the treatment of this disease. However,
no evidence-based recommendations for target volume
definition especially CTV have been provided for con-
formal radiation therapy for pancreatic cancer.
The current study analyzed all available clinical evi-
dence on the pattern of lymph node metastases based
on pathological examination after definitive surgery, and
concluded that the pattern, namely the probability and
sites of lymph node metastasis from tumors originated
from the head or the body/tail of the pancreas can be
followed. In patients with pancreatic head cancer, the
most commonly involved lymph node regions include
lymph nodes around the common hepatic artery, poster-
ior pancreaticoduodenal lymph nodes, lymph nodes
around the superior mesenteric artery, paraaortic lymph
nodes and anterior pancreaticoduodenal lymph nodes.
These nodal regions should be considered as the high-
risk regions and encompassed in CTV. Some of the
above-mentioned nodal groups can be further differen-
tiated anatomically in the context of pancreatic cancer.
For lymph nodes around the superior mesenteric artery
(group 14), the metastatic rate of the subgroup 14c
(lymph nodes at the root of the medial colic artery) was
6.6%, thus encompassing group 14c may not be
Figure 3 Frequency of lymph nodal metastasis of pancreatic cancer.
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Page 8 of 13Table 3 Metastatic rates of subgroups of lymph nodes of pancreatic head cancer (paraaortic lymph nodes not included)
No. Study 8a 8p 11p 11d 12a 12p 12b 13a 13b 14a 14b 14c 14d 17a 17b
3 40/76 35/76 13/76 16/76 5/76 9/76 22/76 13/76
6 22/42 19/42 8/42 11/42 3/42 6/42 13/42 9/42
2 523/3695 205/3030 121/3229 0/4910 180/3887 257/3808 484/3784 1490/2830 1098/3085 764/3282 760/3342
12 22/44 18/44 8/44 9/44 3/44 6/44 11/44 7/44
17 25/49 23/49 10/49 11/49 3/49 7/49 16/49 11/49
Metastatic rate% 14.2 6.8 3.7 0 4.6 6.7 12.8 52.6 36.2 18.5 22.3 6.6 13.3 23.6 22.5
Abbreviations:
8a = lymph nodes of the anterior-superior region (group 8)
8p = lymph nodes of the posterior region (group 8)
11p = proximal splenic lymph nodes (group 11)
11d = distal splenic lymph nodes (group 11)
12a = lymph nodes around the proper hepatic artery (group 12)
12p = lymph nodes around the portal vein (group 12)
12b = lymph nodes around the bile duct (group 12)
13a = lymph nodes above the papilla of Vater (group 13)
13b = lymph nodes below the papilla of Vater (group 13)
14a = lymph nodes at the root of the superior mesenteric artery (group 14)
14b = lymph nodes at the root of the inferior pancreatoduodenal artery (group 14)
14c = lymph nodes at the root of the medial colic artery (group 14)
14d = lymph nodes at the root of the intestinal arteries (group 14)
17a = lymph nodes above the papilla of Vater (group 17)
17b = lymph nodes below the papilla of Vater (group 17)
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3necessary in CTV for radiation therapy. Likewise, lymph
nodes around the common hepatic artery (group 8)
have a number of subgroups. The metastatic rate to
group 8p (lymph nodes of the posterior region) was
seen in 6.8% of cases. However, since such finding was
seen in only one study, exclusion of group 8p cannot be
recommended.
T h ec o l l e c t i v ee v i d e n c ea l s od e m o n s t r a t e dt h a tt h e
probability of metastasis to nodal group 1-7 described
by the JPS including peri-gastric and infrapyloric nodes
are relatively rare (all less than 10%). Therefore, group
1-7 can be excluded from the high-dose coverage during
precision radiation therapy. The metastatic rate to the
hepatoduodenal ligament (group 12) was 7.9%, and
could be considered as a “low-risk” region. However,
once lymphatic invasion occurs, the rate of involvement
raised to 20.7%. In addition, hepatoduodenal ligament
group is a potential lymphatic route to hepatic metasta-
sis [16]. Therefore, it is reasonable to encompass hepa-
toduodenal ligament group in the CTV unless lymphatic
invasion is absent in pathology examination after com-
plete resection.
The extent of cancer including that of lymph node
metastasis is usually associated to certain characteristics
of the disease such as the extent of the primary disease,
differentiation, and lymphatic vessel invasion, etc. How-
ever, the collective data and analyses in the current
study failed to demonstrate such correlation. As most of
the patients included in the 18 studies in our analyses
were surgically resectable, such counterintuitive finding
could only demonstrated that lymph node metastasis
may occur in the earliest stage of pancreatic cancer.
Such phenomenon may indicate the important of adju-
vant therapy in definitive treatment of pancreatic cancer,
and reduced target volume may not be ideal even for
small and/or well-differentiated tumors at early stages.
The most commonly involved lymph node regions in
pancreatic body/tail cancers include those around the
common hepatic artery, lymph nodes around the celiac
trunk, lymph nodes along the splenic artery, lymph
nodes around the superior mesenteric artery, paraaortic
lymph nodes and inferior body lymph nodes. Therefore,
these regions should be included in the target volumes.
With limited data on pancreatic body/tail cancers, no
correlation between lymph node metastatic rates and
tumor characteristics was observed. Therefore, no
change in CTV selection and delineation is recom-
mended according to tumor characteristics for the pan-
creatic body/tail cancers.
Para-aortic lymph nodes, despite its more distant loca-
tion in pancreatic cancer, have relatively high probability
of disease involvement, according to 14 of the 18 studies
included, for both head and body/tail cancers of the
pancreas [1,16-20,23-28,30,31]. Para-aortic nodes can be
categorized according to their anatomic position and the
probability of metastasis in pancreatic cancer. Para-aor-
tic lymph nodes anterior to the aorta and in-between
aorta and vena cava from the celiac artery to the inferior
mesenteric artery had much higher metastatic rates than
those lateral and posterior to the aorta and vena cava
and those anterior to the vena cava (metastatic rates all
<4%). Therefore, high radiation dose regions should
encompass at least the nodes anterior and medial to the
aorta between celiac and inferior mesenteric artery.
One of the recent developments in image technology
that may provide more accurate selection and delinea-
tion of CTV in pancreatic cancer is the use of functional
image studies. The prevailing use of functional imaging
especially FDG-PET/CT may provide more accurate
diagnosis of regional node diagnosis in many neoplasms.
And the effectiveness of FDG-PET/CT in the selection
and delineation of both primary tumor and regional
metastasis has been demonstrated in a number of malig-
nancies including lung cancer and head and neck can-
cers [39-41]. The sensitivity and specificity of FDG-PET/
CT in the diagnosis and evaluation of pancreatic cancer
were reportedly 71-100% and 64-95%, respectively, sig-
nificantly higher than those of CT scans [42,43]. How-
ever, false-positive FDG-PET findings may be seen in
inflammatory conditions, while hyperglycemia and small
tumor sizes may results in false-negative results. In addi-
tion, most of the lymph node metastasis remains unde-
tectable because of their small size, for which a low
sensitivity range between 20%-35% was observed [36,44].
Clearly, the capability of FDG-PET/CT in detecting sub-
clinical disease in lymph node is limited, and the use of
the results of FDG-PET/CT to guide CTV-node delinea-
tion is not feasible at this time.
The pathologic findings summarized in the current
analyses represent a factorial summary of the pattern of
lymph node metastasis in patients with resectable pan-
creatic cancer. However, the clinical value, i.e., the appli-
cation of such results in clinical practice is largely
unknown. In resectable pancreatic cancer, the extent of
treatment to the lymph node is controversial. The
results of a number of retrospective studies from Japan
indicated that extended lymphadenectomy were asso-
ciated with improved long-term survival, and the 5-year
overall survival of patients underwent extended lympha-
denectomy approached 30%-35% [15,45]. However, such
findings were not universally supported from the results
of prospective randomized clinical trials published
recently. Results from most trials indicated that
although extended lymphadenectomy showed similar
perioperative morbidity and mortality as standard lym-
phadenectomy, no long-term survival benefits were
identified [46-48]. Two of these studies reported severe
diarrhea in a high percentage of patients after extended
Sun et al. Radiation Oncology 2010, 5:28
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Page 10 of 13lymphadenectomy [47,48]. Although most physicians
would agree on the necessity to resect regional lympha-
tic areas with high metastatic rate electively
[3,17,18,20,49], the efficacy of radiation therapy to those
areas, with or without extended lymphadenectomy,
remains a focus of clinical trial. In addition, more than
85% of pancreatic cancer cases present as locally
advanced and unresectable disease, and regional metas-
tasis to lymph nodes may be more extensive than in
resectable cases.
Under these circumstances, the collective data pre-
sented in the current analyses serves as a hypothesis gen-
erated for further clinical trials, preferably in prospective
fashion, to investigate the efficacy of elective radiation
therapy to the regional lymph nodes in adjuvant or defi-
nitive treatment using precision radiation therapy. How-
ever, such effort is further complicated by reduced
accuracy of target volume contouring due to movement
caused by respiration [50], and increased treatment
volume to compensate such inaccuracy may cause intol-
erable toxicity if high-dose radiation therapy is imple-
mented [51,52]. In addition, isolated recurrence in the
regional lymph nodes is rare in pancreatic cancer, and
the main mode of treatment failure include both local/
regional and distant metastasis. Nevertheless, improve-
ment in outcome including systemic disease control has
been observed with the use of more effective chemother-
apy agent such as gemcitabine [53]. Furthermore, the
concurrent use of chemotherapy and IMRT in definitive
treatment of pancreatic has been reported [54,55]. To
further evaluate the efficacy of concurrent gemcitabine
and IMRT with dose escalation under active breathing
control (ABC) in the treatment of unresected locally
advanced pancreatic cancer, a Phase II clinical trial has
been initiated in the participating institutions of the cur-
rent analyses. However, due to the limited number of
patients who present with early stage pancreatic cancer
and could achieve complete resection, investigation on
the clinical value of adjuvant radiation therapy to the
high-risk nodal regions in resectable pancreatic cancer
will not be possible without multi-institutional effort.
Conclusions
Regional lymph node metastases in pancreatic cancer
follow a predictable pattern based on the origin of the
disease within pancreas. Clinical target volume of radia-
tion therapy for subclinical disease should be designed
with consideration of the probability of nodal metastasis.
Although clinical investigation is needed to validate the
efficacy of elective radiation therapy to the high-risk
regions, the suggested strategy based on pooled analyses
of clinical evidences forms a reasonable recommenda-
tion of CTV-Node definition in precision radiation ther-
apy of resectable pancreatic cancer.
Acknowledgements
None.
Author details
1Department of Radiation Oncology, Fudan University Shanghai Cancer
Center Department of Oncology, Shanghai Medical College, Fudan
University, Shanghai 200032, China.
2Department of Radiation Oncology,
National University Cancer Institute, National University Health System,
National University of Singapore, Singapore 119074, Republic of Singapore.
Authors’ contributions
WJS collected and analyzed data and performed statistical analysis. WJS and
JL drafted the manuscript. CNL reviewed the data and revised the
manuscript. ZZ and JL designed the study and revised the final version. All
authors have read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 February 2010 Accepted: 15 April 2010
Published: 15 April 2010
References
1. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T,
Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K:
Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas
2004, 28:219-230.
2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE,
Evans RG: Patterns of failure after curative resection of pancreatic
carcinoma. Cancer 1990, 66:56-61.
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK,
Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the
pancreas–616 patients: results, outcomes, and prognostic indicators. J
Gastrointest Surg 2000, 4:567-579.
4. Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after
resection for ductal adenocarcinoma of the pancreas. Is it really
improving? Ann Surg 1995, 221:59-66.
5. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation
and chemotherapy following curative resection. Arch Surg 1985,
120:899-903.
6. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH,
Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant
radiotherapy and 5-fluorouracil after curative resection of cancer of the
pancreas and periampullary region: phase III trial of the EORTC
gastrointestinal tract cancer cooperative group. Ann Surg 1999,
230:776-782.
7. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB: Phase II trial
of preoperative radiation therapy and chemotherapy for patients with
localized, resectable adenocarcinoma of the pancreas: an Eastern
Cooperative Oncology group Study. J Clin Oncol 1998, 16:317-323.
8. Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J,
Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E,
Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R,
Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J,
Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW: Therapy of locally
unresectable pancreatic carcinoma: a randomized comparison of high
dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +
5-fluorouracil), and high dose radiation + 5-fluorouracil: the
Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710.
9. Gastrointestinal Tumor Study Group: Treatment of locally unresectable
carcinoma of the pancreas: comparison of combined-modality therapy
(chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer
Inst 1988, 80:751-755.
10. Chmura SJ, Heimann R: Normal tissue toxicity using intensity modulated
radiation therapy(IMRT) in pancreatic cancer and cholangiocarcinoma.
[Abstract] Proc Am Soc Clin Oncol 2001, 20:1093.
11. Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC,
Lawrence TS, Haken RK, Ben-Josef E: Potential for dose-escalation and
reduction of risk in pancreatic cancer using IMRT optimization with
lexicographic ordering and gEUD-based cost functions. Med Phys 2007,
34:521-529.
Sun et al. Radiation Oncology 2010, 5:28
http://www.ro-journal.com/content/5/1/28
Page 11 of 1312. Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D: A
dosimetric analysis of dose escalation using two intensity-modulated
radiation therapy techniques in locally advanced pancreatic carcinoma.
Int J Radiat Oncol Biol Phys 2006, 65:274-283.
13. Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, Wenz F,
Lohr F: IMRT for postoperative treatment of gastric cancer: covering
large target volumes in the upper abdomen: a comparison of a step-
and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 2004,
59:1236-1244.
14. Japan Pancreas Society: Classification of pancreatic carcinoma. Tokyo:
Kanehara, 2nd English 2003.
15. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H,
Imaoka S, Iwanaga T: Practical usefulness of lymphatic and connective
tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988,
208:215-220.
16. Brunner TB, Merkel S, Grabenbauer GG, Meyer T, Baum U, Papadopoulos T,
Sauer R, Hohenberger W: Definition of elective lymphatic target volume
in ductal carcinoma of the pancreatic head based on histopathologic
analysis. Int J Radiat Oncol Biol Phys 2005, 62:1021-1029.
17. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Ueno K, Tajima H, Elnemr A,
Miwa K: Analysis of paraaortic lymph node involvement in pancreatic
carcinoma: a significant indication for surgery? Cancer 1999, 85:583-590.
18. Sierzega M, Popiela T, Kulig J, Nowak K: The ratio of metastatic/resected
lymph nodes is an independent prognostic factor in patients with node-
positive pancreatic head cancer. Pancreas 2006, 33:240-245.
19. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Mori K, Nakano T,
Takeda T, Konishi I, Miyazaki I: The pattern of lymph node involvement in
carcinoma of the head of the pancreas. A histologic study of the
surgical findings in patients undergoing extensive nodal dissections. Int
J Pancreatol 1993, 13:15-22.
20. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I: Clinical
study of lymphatic flow to the paraaortic lymph nodes in carcinoma of
the head of the pancreas. Cancer 1994, 73:1155-1162.
21. Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M:
Extended lymphadenectomy and vein resection for pancreatic head
cancer: outcomes and implications for therapy. Arch Surg 2003,
138:1316-1322.
22. Cubilla AL, Fortner J, Fitzgerald PJ: Lymph node involvement in carcinoma
of the head of the pancreas area. Cancer 1978, 41:880-887.
23. Nakao A, Harada A, Nonami T, Kaneko T, Nomoto S, Koyama H,
Kanazumi N, Nakashima N, Takagi H: Lymph node metastasis in carcinoma
of the body and tail of the pancreas. Br J Surg 1997, 84:1090-1092.
24. Nagai H, Kuroda A, Morioka Y: Lymphatic and local spread of T1 and T2
pancreatic cancer. A study of autopsy material. Ann Surg 1986, 204:65-71.
25. Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I:
Lymphatic flow and neural plexus invasion associated with carcinoma of
the body and tail of the pancreas. Cancer 1996, 78:2485-2491.
26. Kayahara M, Nagakawa T, Kobayashi H, Mori K, Nakano T, Kadoya N, Ohta T,
Ueno K, Miyazaki I: Lymphatic flow in carcinoma of the head of the
pancreas. Cancer 1992, 70:2061-2066.
27. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S: Outcome
of paraaortic node-positive pancreatic head and bile duct
adenocarcinoma. Am J Surg 2004, 187:736-740.
28. Sakai M, Nakao A, Kaneko T, Takeda S, Inoue S, Kodera Y, Nomoto S,
Kanazumi N, Sugimoto H: Para-aortic lymph node metastasis in
carcinoma of the head of the pancreas. Surgery 2005, 137:606-611.
29. Gerdes B, Ramaswamy A, Bartsch DK, Rothmund M: Peripyloric lymph
node metastasis is a rare condition in carcinoma of the pancreatic head.
Pancreas 2005, 31:88-92.
30. Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Furukawa H, Nakamori S,
Imaoka S, Iwanaga T, Kasugai T: Practical grouping of positive lymph
nodes in pancreatic head cancer treated by an extended
pancreatectomy. Surgery 1997, 121:244-249.
31. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I: Surgical
strategy for carcinoma of the pancreas head area based on
clinicopathologic analysis of nodal involvement and plexus invasion.
Surgery 1995, 117:616-623.
32. Kocher HM, Sohail M, Benjamin IS, Patel AG: Technical limitations of lymph
node mapping in pancreatic cancer. Eur J Surg Oncol 2007, 33:887-891.
33. Hazard L: The role of radiation therapy in pancreas cancer. Gastrointest
Cancer Res 2009, 3:20-28.
34. Withers HR, Peters LJ, Taylor JM: Dose-response relationship for radiation
therapy of subclinical disease. Int J Radiat Oncol Biol Phys 1995,
31:353-359.
35. Willett CG, Clark JW: Update on combined-modality treatment options for
pancreatic cancer. Oncology 2003, 17:29-36.
36. Lemke AJ, Niehues SM, Hosten N, Amthauer H, Boehmig M, Stroszczynski C,
Rohlfing T, Rosewicz S, Felix R: Retrospective digital image fusion of
multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions–a
prospective study with 104 patients. J Nucl Med 2004, 45:1279-1286.
37. De Gaetano AM, Vecchioli A, Minordi LM, Parrella A, Gaudino S, Masselli G,
Savino G: Role of diagnostic imaging in abdominal lymphadenopathy.
Rays 2000, 25:463-484.
38. Hanbidge AE: Cancer of the pancreas: the best image for early
detection–CT, MRI, PET or US? Can J Gastroenterol 2002, 16:101-105.
39. Yu H, Caldwell C, Mah K, Poon I, Balogh J, MacKenzie R, Khaouam N,
Tirona R: Automated radiation targeting in head-and-neck cancer using
region-based texture analysis of PET and CT images. Int J Radiat Oncol
Biol Phys 2009, 75:618-625.
40. Geets X, Lee JA, Castadot P, Bol A, Grégoire V: Potential place of FDG-PET
for the GTV delineation in head and neck and lung cancers. Cancer
Radiother 2009, 13:594-599.
41. Yu J, Li X, Xing L, Mu D, Fu Z, Sun X, Sun X, Yang G, Zhang B, Sun X,
Ling CC: Comparison of tumor volumes as determined by pathologic
examination and FDG-PET/CT images of non-small-cell lung cancer: a
pilot study. Int J Radiat Oncol Biol Phys 2009, 75:1468-1474.
42. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC,
Clavien PA, Hany TF: Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop
imaging for assessing the resectability of pancreatic cancer. J Nucl Med
2008, 49:1408-1413.
43. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F,
Schwaiger M, Roder JD, Siewert JR: Preoperative evaluation of pancreatic
masses with positron emission tomography using 18F-
fluorodeoxyglucose: diagnostic limitations. World J Surg 2000,
24:1121-1129.
44. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimoda M, Kubota K,
Suganuma N, Sugimura K: Performance of Integrated FDG-PET/Contrast-
enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer:
Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and
Enhanced CT. Mol Imaging Biol 2009.
45. Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, Yamaki K,
Nonaka A, Tobe T: Radical pancreatectomy for ductal cell carcinoma of
the head of the pancreas. Cancer 1989, 64:1132-1137.
46. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C,
Klöppel G, Dhaene K, Michelassi F: Standard versus extended
lymphadenectomy associated with pancreatoduodenectomy in the
surgical treatment of adenocarcinoma of the head of the pancreas. Ann
Surg 1998, 228:508-517.
47. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA,
Lillemoe KD: Pancreaticoduodenectomy with or without extended
retroperitoneal lymphadenectomy for periampullary adenocarcinoma.
Comparison of morbidity and mortality and short-term outcome. Ann
Surg 1999, 229:613-624.
48. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N,
Sargent DJ: Pancreas Cancer Working Group: A prospective randomized
trial comparing standard pancreatoduodenectomy with
pancreatoduodenectomy with extended lymphadenectomy in
resectable pancreatic head adenocarcinoma. Surgery 2005, 138:618-630.
49. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S: Outcome
of paraaortic node-positive pancreatic head and bile duct
adenocarcinoma. Am J Surg 2004, 187:736-740.
50. Bussels B, Goethals L, Feron M, Bielen D, Dymarkowski S, Suetens P,
Haustermans K: Respiration-induced movement of the upper abdominal
organs: A pitfall for the three-dimensional conformal radiation treatment
of pancreatic cancer. Radiother Oncol 2003, 68:69-74.
51. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K,
Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN,
Janjan NA: Combining gemcitabine with radiation in pancreatic cancer:
Understanding important variables influencing the therapeutic index.
Semin Oncol 2001, 28(3 Suppl 10):25-33.
52. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W,
Hohenberger W, Sauer R: Phase I trial of strictly time-scheduled
Sun et al. Radiation Oncology 2010, 5:28
http://www.ro-journal.com/content/5/1/28
Page 12 of 13gemcitabine and cisplatin with concurrent radiotherapy in patients with
locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003,
55:144-153.
53. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR,
Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA,
Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit
with gemcitabine as first-line therapy for patients with advanced
pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
54. Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, Zhou RH, Lu DQ: Intensity
modulated radiation therapy and chemotherapy for locally advanced
pancreatic cancer: results of feasibility study. World J Gastroenterol 2003,
9:2561-2564.
55. Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF,
McDermott P, Burmeister J, Bossenberger T, Philip PA: Intensity-modulated
radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Int J Radiat Oncol Biol Phys 2004, 59:454-459.
doi:10.1186/1748-717X-5-28
Cite this article as: Sun et al.: Proposing the lymphatic target volume
for elective radiation therapy for pancreatic cancer: a pooled analysis of
clinical evidence. Radiation Oncology 2010 5:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sun et al. Radiation Oncology 2010, 5:28
http://www.ro-journal.com/content/5/1/28
Page 13 of 13